Newsletter Tool

Today's Rundown

Featured Story

Novartis halts US production of radioligand cancer therapies, citing potential quality issues

By Angus Liu

Novartis is hitting the brakes on manufacturing its two marketed radioligand therapies for treating cancer, suspending supply in North America merely weeks after trumpeting an FDA approval.

Big pharma resisting temptation for biotech M&A spree until prices drop further

By James Waldron

Plunging valuations may be forcing biotechs to lay off staff and strip back their pipelines, but Big Pharma is not yet tempted to go on an M&A spree. Judging by first-quarter earnings calls over the past two weeks, CEOs of many of the world’s pharma giants believe biotech prices still have a way to drop before they became irresistible acquisitions.

Senators decry lack of 'sunlight' on PBM processes, push for reforms in transparency

By Robert King

Bipartisan senators are pushing for more transparency and reforms in the pharmacy benefit management industry amid concerns about its role in tackling high drug prices.

BD tightens up revenue guidance after completing Embecta diabetes spinoff

By Conor Hale

BD said it would move forward as a more agile, yet stable organization, with a stronger focus on the types of hardware that are always in demand within the healthcare industry.

Cerebral stops prescribing Adderall for new ADHD patients as reports of DEA investigation surface

By Heather Landi

Telehealth startup Cerebral said Wednesday it would stop writing prescriptions for Adderall, Ritalin and other controlled substances to new ADHD patients. The problems at Cerebral intensified Wednesday as Insider reported that the Drug Enforcement Agency (DEA) is investigating the company.

Amid BeiGene's global expansion push, CEO Oyler scores 16% pay raise to $16.7M

By Kevin Dunleavy

BeiGene has rewarded CEO John Oyler with $16.75 million in compensation for 2021, according to an SEC filing. It was a 16% increase from his $14.41 million package in 2020. The company also reported a 146% increase in revenue for the first quarter due largely to increased sales of chemo drug Brukinsa in the U.S. and China.

Intellia puts pedal to the metal as 3 new candidates prepped for clinic

By Annalee Armstrong

Intellia has three candidates from its gene editing and cell therapy platform headed to a clinic near you in the next year or so. The company previewed its next steps in a first-quarter earnings call Thursday morning, detailing recent clinical activities and the upcoming data readouts that will define the CRISPR biotech for years to come.

BioCryst's voluntary pause turns FDA-hold as investigation reveals likely culprit behind safety signals

By Max Bayer

A voluntary pause for BioCryst Pharmaceuticals' complement-mediated disease therapy has been upgraded to a partial FDA clinical hold, but the biotech now believes it has an idea of what's behind the safety signals that have ground the program to a halt.

Sidekick Health nets $55M to bolster digital therapeutics programs

By Conor Hale

Looking to no longer play second fiddle, digital therapeutics developer Sidekick Health aims to expand its video-game-like healthcare platform.

CVS Health hits 44M unique digital customers in Q1

By Paige Minemyer

The healthcare giant also beat the Street on revenue, posting $76.8 billion for the first quarter.

Intercept sells Ocaliva rights outside the US after NASH development woes